With a fundraising roadshow in the offing, Affitech A/S bolstered its pipeline by taking back in house a preclinical antivascular endothelial growth factor (VEGF) antibody development program it previously had licensed out to Peregrine Pharmaceuticals Inc. (BioWorld International) Read More
